Defining Medication Exposure When Analyzing Real-World Data
- Alecia Clary,
- Nancy Lin D,
- Tamar Lasky
, - matthew reynolds,
- Anand Chokkalingam,
- Carla Rodriguez-Watson
Alecia Clary
Reagan-Udall Foundation for the FDA
Corresponding Author:aclary@reaganudall.org
Author ProfileTamar Lasky
United States Food and Drug Administration Office of Data Analytics & Research Office of the Commissioner
Author ProfileCarla Rodriguez-Watson
Reagan-Udall Foundation for the FDA
Author Profile29 Nov 2022Submitted to Pharmacoepidemiology and Drug Safety 29 Nov 2022Submission Checks Completed
29 Nov 2022Assigned to Editor
29 Nov 2022Review(s) Completed, Editorial Evaluation Pending
09 Dec 2022Reviewer(s) Assigned
23 Jan 2023Editorial Decision: Revise Minor
02 Mar 20231st Revision Received
02 Mar 2023Submission Checks Completed
02 Mar 2023Assigned to Editor
02 Mar 2023Review(s) Completed, Editorial Evaluation Pending
14 Mar 2023Editorial Decision: Accept
